Aviragen Therapeutics is a pioneering biopharmaceutical company with a strong commitment to combatting serious infectious diseases through innovative therapies. Founded in 1984, the company has dedicated its efforts to discovering and developing products aimed at preventing and treating potentially life-threatening infectious diseases.
The company's current focus is on two Phase 2 clinical-stage product candidates. The first, laninamivir octanoate, is intended for the treatment of influenza A and B infections in the United States, with significant financial support of up to $231 million through a contract with the U.S. Office of Biomedical Advanced Research and Development Authority (BARDA). The second candidate is vapendavir, an oral broad-spectrum capsid inhibitor targeting enteroviruses, including human rhinovirus.
In addition to its clinical-stage products, Aviragen Therapeutics also has preclinical programs focused on developing treatments for respiratory syncytial virus, further demonstrating its commitment to addressing a broad range of infectious diseases.
Operating in the biotechnology industry, the company's drive to combat infectious diseases presents a compelling opportunity for investors seeking to support groundbreaking solutions in healthcare.
